Story
Qualcomm Extends Apple Patent Licensing Deal, Securing Long-Term Revenue

Summary
Qualcomm has announced a renewed global patent licensing agreement with Apple, effective April 1, 2027, providing investors with clarity on a critical, high-margin revenue stream.
Qualcomm (NASDAQ: QCOM) announced it has renewed its global patent licensing agreement with Apple, securing a key source of revenue for the long term. The extension, which takes effect on April 1, 2027, helped lift the chipmaker's stock amid a wider market downturn, underscoring the deal's importance to investors.
Deal Provides Revenue Clarity
The announcement provides investors with much-needed certainty regarding one of the technology sector's most significant commercial relationships. Following the news, Qualcomm shares ticked up 0.2%, paring earlier losses, as per Investing.com.
"We are pleased to extend the Apple license agreement," said John Han, Executive Vice President and General Manager of Qualcomm Technology Licensing, in a statement confirming the deal. The extension ensures the continuation of highly profitable royalty payments from Apple to Qualcomm.
AdContext of a Complex Partnership
The agreement is notable given the historically contentious relationship between the two Silicon Valley giants. Apple has been actively working to reduce its reliance on Qualcomm's hardware, acquiring Intel's modem business and developing its own in-house cellular chips to power future devices.
However, Qualcomm holds foundational patents essential for modern cellular connectivity. This intellectual property means that even if Apple successfully transitions to its own modem silicon in future iPhones, it must still pay Qualcomm licensing fees to use the underlying technology, a crucial detail this new agreement solidifies for the coming years.
Read next
More on Stocks
Asia and Europe Tipped for Equity Market Leadership Over Next 12 Months
Market analysis suggests Asia ex-Japan offers the highest growth potential, albeit with significant risk, while European equities present a compelling value opportunity as investors look beyond U.S. mega-caps.

aTyr Pharma Shares Surge on FDA Agreement for Pivotal Efzofitimod Trial
Shares of the biopharmaceutical company jumped after it announced an agreement with the U.S. FDA on the design of a Phase 3 study for its lead drug candidate, efzofitimod, in patients with pulmonary sarcoidosis.

Bernstein Taps Amphenol, TE Connectivity as Top Picks for Data Center Growth
Analysts at Bernstein have identified Amphenol and TE Connectivity as leading stocks in the interconnect sector, poised to benefit from the ongoing expansion of data center infrastructure.

AMD Stock Slides From 52-Week High on Summit Disappointment, Analyst Downgrade
Shares of Advanced Micro Devices fell in pre-market trading, pulling back from a recent high as investor hopes for eased U.S.-China tech tensions faded and a recent analyst downgrade cited valuation concerns.